After randomization of @ patients in remission , patients whose dose had been increased to @mg escitalopram after @ weeks of open-label treatment had a high escitalopram relapse rate ( @ % ) and a placebo relapse rate of @ % with a hazard ratio ( HR ) of @ , whereas patients titrated to @mg escitalopram at Weeks @ or @ had a high placebo relapse rate ( @ % ) and an escitalopram relapse rate of @ % with a HR = @ .